期刊
ACTA BIOCHIMICA ET BIOPHYSICA SINICA
卷 43, 期 4, 页码 248-257出版社
OXFORD UNIV PRESS
DOI: 10.1093/abbs/gmr007
关键词
transcriptional coactivator; metabolic syndrome; PGC-1; mitochondrial biogenesis; energy metabolism
资金
- National Natural Science Foundation of China [30870928]
- Research Fund for the Doctoral Program of Higher Education of China [20103207110007]
- Fok Ying Tong Education Foundation [121022]
- Educational Commission of Jiangsu Province [09KJA180004]
- NIH [DK077086]
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK077086] Funding Source: NIH RePORTER
Chronic disruption of energy balance, where energy intake exceeds expenditure, is a major risk factor for the development of metabolic syndrome. The latter is characterized by a constellation of symptoms including obesity, dyslipidemia, insulin resistance, hypertension, and nonalcoholic fatty liver disease. Altered expression of genes involved in glucose and lipid metabolism as well as mitochondrial oxidative phosphorylation has been implicated in the pathogenesis of these disorders. The peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) family of transcriptional coactivators is emerging as a hub linking nutritional and hormonal signals and energy metabolism. PGC-1 alpha and PGC-1 beta are highly responsive to environmental cues and coordinate metabolic gene programs through interaction with transcription factors and chromatin-remodeling proteins. PGC-1 alpha has been implicated in the pathogenic conditions including obesity, type 2 diabetes, neurodegeneration, and cardiomyopathy, whereas PGC-1 beta plays an important role in plasma lipoprotein homeostasis and serves as a hepatic target for niacin, a potent hypotriglyceridemic drug. Here, we review recent advances in the identification of physiological and pathophysiological contexts involving PGC-1 coactivators, and also discuss their implications for therapeutic development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据